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Abstract Several large, well-controlled clinical trials
have now established that the aromatase inhibitors (AIs),
including letrozole, anastrozole, and exemestane, are more
eVective than tamoxifen when used as adjuvant endocrine
therapy in postmenopausal women with breast cancer. Yet,
it is an open question as to how these drugs should be best
integrated into the adjuvant treatment regimen. Both letroz-
ole and anastrozole have shown eYcacy over tamoxifen
when used as initial adjuvant therapy (initiated just follow-
ing surgery for breast cancer), while exemestane and anas-
trozole have been used as switching adjuvant therapy, i.e.,
following 2–3 years of initial adjuvant tamoxifen therapy,
with proven eYcacy over continued tamoxifen. Studies
demonstrate that recurrence risk peaks in the early period
after surgery, and that distant metastases in particular,
accounting for most of the early recurrences, have worse
survival rates when compared with other types of recur-
rences. Treatments that reduce recurrences, especially dis-
tant metastases, in this early period are therefore likely to
improve overall survival (OS) and reduce mortality from
breast cancer. In this review, we discuss early recurrence
risk among postmenopausal women with successfully
treated early breast cancer, the eYcacy of the diVerent AIs
in reducing early recurrences and distant metastases when
incorporated into adjuvant therapy, and the evidence for
increased OS when AIs are used as initial or switch adju-
vant therapy.
Keywords Adjuvant therapy · Anastrozole · Early breast 
cancer · Exemestane · Letrozole · Distant recurrence · 
Tamoxifen
Introduction
There has been a sharp decrease in the incidence of breast
cancer in the United States, which has been associated with
the decreased use of hormone replacement therapy; how-
ever, cancer statistics continue to identify breast cancer as
the single most commonly diagnosed cancer in women
worldwide (Ravdin et al. 2006; Boyle and Ferlay 2005;
Parkin et al. 1999) and a leading cause of cancer deaths
among women, with nearly one million new cases diag-
nosed each year and about 373,000 cancer-related deaths
yearly (Guarneri and Conte 2004). In Europe, breast cancer
accounts for more than 25% of all newly diagnosed cancers
and nearly 18% of all cancer-related deaths (Tyczynski
et al. 2004). Early beliefs from the late 1800s that radical
mastectomy-treated patients could be largely cured of
breast cancer were proven wrong when it was found that
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the procedure (Cianfrocca and Goldstein 2004). In fact,
relapse most commonly occurs in the form of distant metas-
tases, even in 20–30% of node-negative (N0) patients
(Cianfrocca and Goldstein 2004). The risk of distant metas-
tases is much greater than the risk of locoregional recur-
rences, especially during the Wrst few years post surgery
(Mansell et al. 2006), and a distant metastatic event is par-
ticularly devastating for patients because at this stage, the
cancer stops being curable and is associated with decreased
survival (Lamerato et al. 2005).
Adjuvant chemotherapy and/or endocrine therapy is now
the recommended norm to minimize the risk of recurrence
among patients whose breast cancer has been diagnosed
and surgically treated. Adjuvant therapy is not without
risks, however, and patients wishing to reduce their recur-
rence risk must balance this beneWt with any potential
adverse events (AEs) associated with the adjuvant treat-
ment. Assessing recurrence risk and deWning which patients
should undergo adjuvant therapy is therefore critical in the
design of eVective interventions.
The risk of recurrence can be substantial, especially in
those patients with evidence of tumor dissemination to
local lymph nodes; those with large or high grade tumors;
those with low or no expression of hormonal receptor,
including estrogen receptor (ER) in their tumors; and those
whose tumors express known adverse prognostic indica-
tors, such as the proto-oncogene c-erbB-2 (human epider-
mal growth factor receptor 2/neu) (Cianfrocca and
Goldstein 2006). Although any type of disease recurrence is
detrimental to the subsequent survival of breast cancer
patients, distant metastases are a particularly ominous
event, as this indicates the progression of disease to a
largely incurable and ultimately fatal stage. Thus, while the
goal of any adjuvant therapy is to prevent disease recur-
rence overall, those treatments that prove to prevent or sig-
niWcantly reduce distant metastases are likely to provide the
most beneWt for patients in terms of overall survival (OS)
(Lamerato et al. 2005; Pantel and BrakenhoV 2004).
Adjuvant endocrine therapy is the standard treatment for
postmenopausal women with breast cancer, as most breast
cancers depend on estrogen for growth, and 5 years’ treat-
ment with tamoxifen, a selective ER modulator, has been
the standard of care for many years (EBCTCG 2005). How-
ever, the aromatase inhibitors (AIs) have been approved in
this indication and have displaced tamoxifen as the stan-
dard adjuvant treatment for postmenopausal women with
endocrine-sensitive breast cancer. AIs act to inhibit the con-
version of peripheral androgens to estrogen in postmeno-
pausal women, eVectively reducing plasma estrogen to
near-undetectable levels (Choueiri et al. 2004; Dixon et al.
2006). The AIs anastrozole, letrozole, and exemestane have
been introduced for the adjuvant treatment of breast cancer
over the latter part of the past decade, and their use has
been approved in selected treatment settings. With this
addition of the AIs to the adjuvant treatment armamentar-
ium, there is considerable debate over the most eVective
endocrine treatment strategy for postmenopausal women
who have undergone successful surgery for early breast
cancer. Results of the Arimidex, Tamoxifen, Alone or in
Combination (ATAC) and Breast International Group (BIG
1-98) clinical trials suggest that anastrozole and letrozole
are, respectively, more eVective than tamoxifen in reducing
recurrences when used as initial adjuvant treatment (Baum
et al. 2002, 2003; Howell et al. 2005; Thurlimann et al.
2005). Other results from the Intergroup Exemestane Study
(IES), the Italian-Tamoxifen-Arimidex (ITA) study, the
Austrian Breast Cancer Study Group (ABCSG)-8 trial, and
the Arimidex-Nolvadex (ARNO)-95 trial suggest that
switching to exemestane or anastrozole following between
2 and 3 years of tamoxifen therapy is more eVective than
continuing tamoxifen out to 5 years (Coombes et al. 2004,
2007; Boccardo et al. 2005a; Jakesz et al. 2005a).
As relapses occur frequently during the Wrst 5 years after
diagnosis (Saphner et al. 1996), this time period is critical
to preventing distant metastases and breast cancer-related
mortality among patients. It is currently unclear which of
these early adjuvant treatment strategies, if any, is superior
to the others in the management of early breast cancer, or
whether a particular strategy beneWts any speciWc subgroup
of patients. In this review, we discuss the risk of early
breast cancer recurrence and the eYcacy of diVerent adju-
vant treatment strategies involving AIs and tamoxifen in
reducing this risk, to help physicians choose the treatment
regimen that provides the most eVective recurrence prophy-
laxis for their patients.
Early recurrence risk
A sizable proportion of breast cancer recurrences may
occur in the early stages of adjuvant therapy. One study of
more than 3,500 women with breast cancer undergoing
adjuvant therapy (median follow-up 8.1 years) suggests
that the greatest hazard for breast cancer recurrence occurs
during the Wrst few years after primary surgery; this was
true for all degrees of nodal status, all sizes of primary
tumors, and among both menopausal and postmenopausal
patients (Saphner et al. 1996). Another more recently pub-
lished investigation of more than 2,500 patients, 456 of
whom had local, regional, or distant relapse, found that
79% of all recurrences occurred within the Wrst 5 years, and
well over half (58%) occurred within the Wrst 3 years fol-
lowing surgery (Elder et al. 2006). The site of recurrence
also had a signiWcant impact on disease-speciWc survival in
this cohort; patients with a local recurrence had signiWcantly123
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rence at regional lymph nodes or distant metastases (Fig. 1)
(Elder et al. 2006). Similar Wndings were reported in a ret-
rospective cohort study of US patients (N = 1,616) with
early breast cancer (Lamerato et al. 2005). In this study, the
risk of dying was found to be over three times greater for
patients with distant metastases as compared with a locore-
gional or contralateral recurrence (Fig. 2). These results
suggest that while any recurrence of breast cancer is detri-
mental to long-term outcome, early distant metastases have
the greatest impact; median survival following an isolated
local recurrence has been reported to be 12.9 years,
whereas the corresponding survival following a Wrst distant
metastasis event is only 2.2 years (Lê et al. 2002).
Predictors for early relapse (within 2.5 years from diag-
nosis) are similar to those for adverse breast cancer progno-
sis overall, and the results of three studies are summarized
in Table 1. The collective results of these analyses suggest
that factors such as large tumor size, grade III pathology,
low ER positivity, and increasing lymph node involvement
are important to identify patients who are at the greatest
risk for early recurrence, and who therefore should be
treated aggressively with the most eVective adjuvant ther-
apy from the start (McArthur et al. 2005; Mansell et al.
2006; Mauriac et al. 2007). Yet, even for small tumors in
the lowest risk category (N0, G1 tumors <1 cm), the 10-
year risk of breast cancer recurrence is unexpectedly high,
at 12% in the absence of adjuvant therapy (Chia et al.
2004).
It has been found that distant metastases comprise the
majority of recurrence events that occur early in the course
of breast cancer (Mansell et al. 2006). One study demon-
strated that distant metastases occurred in 150 of 309
patients (49%), and that 77 of these 150 distant metastases
(51%) occurred during the Wrst 18 months of follow-up
(Kryj et al. 1997). In multivariate analysis, the number of
involved axillary lymph node and extracapsular invasion
were found to be the most signiWcant and independent fac-
tors involved in the development of distant metastases
(P < 0.0001) (Kryj et al. 1997). Similar Wndings of an asso-
ciation between distant metastases and increasing lymph
node positivity were reported in a study of breast cancers
detected by screening or symptoms in the West Midlands,
United Kingdom (Lawrence et al. 2005). However, the risk
of developing an early distant metastasis is also present in
the N0 patient population. One study estimated Wrst distant
metastases to occur at a rate of approximately 1–2% per
month, 2–4% per month, and 3–6% per month in T1
patients (tumor diameter 1–7 cm) who were N0, had 1–3
positive nodes, or had >3 positive nodes, respectively
(Thames et al. 1999). Another study found the rate of early
distant metastases to be between 6 and 8% in the N0
patients (Kryj et al. 1997). Other less signiWcant predictors
of distant metastases were tumor size and stage (P < 0.001),
age (P < 0.003), and hormone responsiveness (P < 0.04)
(Kryj et al. 1997).
Collectively, these studies indicate that as both N0 and
node-positive (N+) patients, especially those with increas-
ing tumor size and grade, are at substantive risk for early
recurrences, and as the development of early distant metas-
tases increases the risk of dying from the disease, these
patients are candidates for early aggressive adjuvant ther-
apy.
Adjuvant tamoxifen treatment
Given the adverse impact on OS associated with recurrence
and especially early distant metastases, as outlined above,
those adjuvant therapies that are proven to reduce the risk
of early distant metastases are also the most likely to have a
signiWcant beneWcial eVect on OS. In the case of about
5 years of therapy with tamoxifen vs. not (in ER+ breast
Fig. 1 5-Year disease-speciWc survival of breast cancer patients hav-
ing local recurrence (LR), recurrence at regional lymph nodes (RNR),
or distant recurrence (DR). Disease-speciWc survival for LR was sig-
niWcantly diVerent from RNR or DR patients (P < 0.0001) (Data from
Elder et al. 2006)
Fig. 2 Hazard ratio for death in patients with no recurrence (No R),
contralateral recurrence (CR), locoregional recurrence (LRR), or dis-
tant recurrence (DR). The associated P-value for comparison with No
R group is shown (Data from Lamerato et al. 2005)123
908 J Cancer Res Clin Oncol (2007) 133:905–916cancer patients), results of the Oxford meta-analysis have
demonstrated signiWcant reductions in both disease recur-
rence (41%) and breast cancer speciWc mortality (34%).
However, while most of the divergence between treatments
in disease recurrence occurs during the Wrst 5 years on
treatment, the eVect on breast cancer speciWc mortality is
not observed until the period between 5 and 15 years
(EBCTCG 2005). These Wndings are consistent with the
notion that early reductions in recurrence can ultimately
lead to improved survival for breast cancer patients, and
argue for the early use of adjuvant therapy as a means to
improve survival. In one study of 402 patients (median fol-
low-up 50 months), allocation to adjuvant chemotherapy
(88.8% of patients), tamoxifen after chemotherapy (38% of
patients), or tamoxifen alone (11.2% of patients) within
44 days after surgery was found to be associated with sig-
niWcantly improved OS (P < 0.05) but not disease-free sur-
vival (DFS) (Durnali et al. 2006).
Despite the beneWt of large patient numbers and
extended follow-up for many studies, and the time-proven
beneWts in terms of preventing recurrences and breast can-
cer speciWc mortality (EBCTCG 2005, 2006), there are a
number of drawbacks to the use of tamoxifen as an adju-
vant therapy for early breast cancer patients. The use of
tamoxifen has been associated with serious complications
including stroke, thromboembolism, and endometrial can-
cer. In the National Surgical Adjuvant Breast and Bowel
Project (NSABP) P1 study examining tamoxifen relative to
placebo in women at increased risk of breast cancer,
patients allocated to tamoxifen had a 2.5-fold increased risk
of invasive endometrial cancer, which occurred predomi-
nantly in women older than 50 years, a 1.6-fold increased
risk of stroke, a 1.14-fold increased risk of developing cata-
racts, a one- to six-fold increased risk of deep vein throm-
bosis, and threefold increased risk of pulmonary embolus,
the latter two events again occurring mainly in women 50
and older (Fisher et al. 1998). Other studies have conWrmed
the increased risk of thromboembolic events (pulmonary
embolus and deep vein thrombosis), endometrial cancer,
and stroke (McDonald et al. 1995; Braithwaite et al. 2003).
In addition, gynecological events including hot Xashes were
reported to be “quite a bit or extremely” bothersome in
nearly half of the patients on tamoxifen (45.7%), and vagi-
nal discharge that was “moderately bothersome or worse”
occurred in about a third of the patients on tamoxifen (29%)
in the NSABP P1 trial (Fisher et al. 1998). These events
may limit the tolerability of adjuvant tamoxifen, depending
upon the individual patient. Among older patients (55 and
older), the occurrence of side eVects was associated with a
fourfold higher rate of tamoxifen discontinuation; most
troublesome among these events were depression, nausea,
vision problems, and vaginal bleeding (Demissie et al.
2001). Tamoxifen is also associated with an excess of seri-
ous AEs (SAEs) such as endometrial cancer and venous
thromboembolic events early on, in the Wrst 2 years of treat-
ment (Cuzick et al. 2006; DuVy 2006).
There is also some evidence from past clinical trials that
tamoxifen is more eVective in preventing locoregional
recurrences as compared with distant metastases (Ludwig
1984; NATO 1988; Rutqvist et al. 1987). Given the detri-
mental eVect of distant metastases as compared with loco-
regional recurrences on 5-year survival (Fig. 1), it is
important to consider the eYcacy of adjuvant therapies in
preventing distant metastases at the earliest possible time
point. Results from the Oxford meta-analysis also indicate
an approximately 15% overall relapse rate within 5 years
for patients allocated to about 5 years of tamoxifen, with an
approximately 8% incidence of breast cancer speciWc mor-
tality over the same time interval (EBCTCG 2005). Certain
patient subgroups, including those with polymorphisms in
the tamoxifen metabolizing enzyme cytochrome P D26,
have also been shown to be more likely than others to
relapse while on tamoxifen (wt/*4 or *4/*4 genotype vs.
wt/wt; 50% vs. 20.4%; P = 0.042), and such patients will
Table 1 Predictive factors for early disease recurrence (within 2.5 years) in studies of breast cancer patients (McArthur et al. 2005; Mansell et al.
2006; Mauriac et al. 2007)
NR not reported
a Factors that discriminated between early and late recurrence and the associated P-values
Predictive factors Studies N (follow-up)
McArthur et al. 4,159 (7.4 years) Mansell et al. 5,589 (60 months) Mauriac et al. 5,980 (24 months)
Age Not predictive Increasing age (P = 0.003)a NR
Tumor size Not predictive Increasing tumor size (P = 0.003)a Large tumor size (P = 0.001)
Tumor grade Increasing grade (P < 0.001) Increasing grade (P < 0.01) Increasing grade (P < 0.001)
Nodal involvement Increasing lymph node 
involvement (P < 0.001)
Increasing lymph node 
involvement (P < 0.01)




ER expression moderate/high 
vs. low (P = 0.005)
Unknown ER status vs. 
ER+ (P = 0.03)a
Absence of both ER/progesterone 
receptor being positive (P < 0.001)123
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Santiago et al. 2006). Clearly, there is evidence that a select
group of patients is likely resistant to tamoxifen from the
outset and would beneWt from a more eVective initial adju-
vant therapy. We review below the clinical evidence that
AIs are more eVective than tamoxifen when used in the ini-
tial adjuvant setting (i.e., monotherapy with an AI or
tamoxifen immediately following surgery for 5 years) or in
the switch adjuvant setting (i.e., a switch to an AI following
completion of 2 to 3 years of tamoxifen).
Trials of initial adjuvant therapy with AIs
ATAC trial
The ATAC trial was originally designed as a three-arm
study comparing anastrozole, tamoxifen, or the combina-
tion as initial adjuvant therapy. However, as the initial anal-
ysis (33.3 months’ follow-up) failed to demonstrate any
beneWt of the combination therapy arm over tamoxifen
alone, this arm was subsequently discontinued (Baum et al.
2002, 2003). The most recent available analysis of this trial,
obtained at a median of 68 months’ follow-up (Howell
et al. 2005), indicates a signiWcant beneWt of anastrozole
over tamoxifen in DFS and time to distant metastases
(TTDM) in the overall intent-to-treat population (Table 2),
with a similar improvement in DFS [hazard ratio
(HR) = 0.83; P = 0.005] observed in the subgroup of hor-
mone receptor-positive (HR+) patients. Of note, TTDM
was not signiWcantly improved in the HR+ population
(HR = 0.84; P = 0.06). OS was thus similar for anastrozole
vs. tamoxifen (Table 2), and the beneWt of anastrozole in
breast cancer speciWc mortality did not reach signiWcance in
the overall population (Table 2) (Howell et al. 2005). Of
note, a recent analysis of the ATAC data estimated that the
use of anastrozole in lieu of tamoxifen as initial adjuvant
therapy would prevent 40, 17, and 14 recurrences, distant
metastases, and deaths following recurrence, respectively,
at 2.5 years and 82, 44, and 28 of these events, respectively,
at 5 years (Houghton 2005).These data suggest that at 2.5
and 5 years of therapy, anastrozole was associated with
fewer Wrst events, recurrences, and deaths than was tamoxi-
fen; most of the early impact of anastrozole was on locore-
gional and contralateral breast cancer recurrences rather
than on distant metastases (Houghton 2006). In terms of
safety, there was no diVerence in the overall incidence of
AEs between the arms (94% vs. 95%, respectively),
although there were signiWcantly fewer treatment-related
AEs (61% vs. 68%; P < 0.0001), AEs leading to with-
drawal (11% vs. 14%, P = 0.0002), treatment-related AEs
leading to withdrawal (6% vs. 9%; P = 0.0005), SAEs
(33% vs. 36%, P = 0.03), treatment-related SAEs (5% vs.
9%; P < 0.0001), and SAEs leading to withdrawal (5% vs.
6%; P = 0.04) in the anastrozole arm (ATAC 2006). When
compared with tamoxifen, there was a signiWcantly higher
incidence of fractures (11% vs. 8%; P < 0.0001) but not in
patients with normal bone density at baseline. Incidences of
osteopenia and osteoporosis (11% vs. 7%; P < 0.0001) and
hypercholesterolemia (9.0% vs. 3.0%; P < 0.0001) were
also signiWcantly higher in the anastrozole arm (ATAC
2006). More ischemic cardiovascular events occurred in the
anastrozole arm than in the tamoxifen arm, but the diVer-
ence was not signiWcant (4.1% anastrozole vs. 3.4% tamox-
ifen; P = 0.1). The incidences of endometrial cancer,
thromboembolic events, vaginal bleeding, hot Xashes, and
vaginal discharge, on the other hand, all favored the use of
anastrozole over tamoxifen (Howell et al. 2005).
BIG 1-98 trial
The BIG 1-98 trial was designed as a four-arm trial com-
paring an AI (letrozole) with tamoxifen as initial adjuvant
therapy (either letrozole or tamoxifen for 5 years following
surgery) or as sequential adjuvant therapy (letrozole for
2 years followed by tamoxifen for 3 years, or tamoxifen for
2 years followed by letrozole for 3 years) (Thurlimann
et al. 2005). To increase its statistical power comparing
upfront letrozole with tamoxifen, the Wrst analysis included
events occurring in the sequential arms with tamoxifen or
letrozole as initial therapy. The results of this Wrst primary
core analysis (n = 4,003 letrozole, n = 4,007 tamoxifen), at
a median of 25.8 months’ follow-up, have shown a signiW-
cant beneWt of initial adjuvant therapy with letrozole, with a
19% improvement in DFS (HR = 0.81; P = 0.003) over
tamoxifen and a 27% reduction in the risk of distant metas-
tases over tamoxifen (HR = 0.73; P = 0.001). Results of the
primary core analysis showed a total of 177 distant metasta-
ses events (4.4%) in the letrozole arm compared with 232
(5.8%) in the tamoxifen arm (Thurlimann et al. 2005). Pro-
tocol-speciWed subgroup analysis from BIG 1-98 also dem-
onstrated a signiWcant DFS beneWt with letrozole over
tamoxifen among those subgroups of patients who may be
at increased risk for early distant metastases, including
those with N+ disease (HR = 0.71; 95% CI 0.59–0.85;
P < 0.001), those with tumors >2 cm (HR = 0.76; 95% CI
0.63–0.92; P = 0.004), and those receiving prior chemo-
therapy (HR = 0.70; 95% CI 0.54–0.92; P = 0.01) (Thurli-
mann et al. 2005).
The safety proWle of letrozole vs. tamoxifen in this initial
analysis showed a higher incidence of fractures (5.7% vs.
4.0%; P < 0.001), arthralgia (20.3% vs. 12.3%; P < 0.001),
hypercholesterolemia [5.4% vs. 1.2% (in patients who had
normal baseline values that then became 1.5 times higher
than the upper normal limits)], and cardiac failure (0.8% vs.
0.4%; P = 0.01) in the letrozole group, while the tamoxifen123


















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































J Cancer Res Clin Oncol (2007) 133:905–916 911group showed signiWcantly more thromboembolic events
(3.5% vs. 1.5%; P < 0.001), vaginal bleeding (6.6% vs.
3.3%; P < 0.001), hot Xashes (38.0% vs. 33.5%;
P < 0.001), and night sweats (16.2% vs. 13.9%; P = 0.004)
(Thurlimann et al. 2005; Letrozole 2005).
More recently, results from the exploratory analysis
restricted to the two monotherapy arms, with a 51-month
follow-up, have conWrmed those Wndings (n = 2,463 letroz-
ole and n = 2,459 tamoxifen). The results continue to show
a beneWt of letrozole over tamoxifen, with an 18% improve-
ment in DFS (HR = 0.82; P = 0.007) and a 19% signiWcant
reduction in the risk of distant metastases (P = 0.03)
(Coates et al. 2007) (Table 2). The cumulative incidence of
breast cancer relapse was 13.4% in the tamoxifen arm vs.
10.2% in the letrozole arm, a diVerence of 3.2%
(P = 0.005). In addition, subgroup analysis continued to
show the beneWt of letrozole over tamoxifen in DFS in the
N+ group (n = 2,067; HR = 0.77; P = 0.004), the chemo-
therapy-treated group (n = 1,232; HR = 0.74; P = 0.03),
and those with tumors >2 cm (n = 1,858; HR = 0.79;
P = 0.01) (Coates et al. 2007). An emerging beneWt in the
N¡ patient population as a 12% reduction in the risk of
recurrence is also seen with longer follow-up (HR = 0.88;
P = 0.26) (Coates et al. 2007). The safety results in this
exploratory monotherapy arm analysis at 51 months were
generally similar to those obtained in the initial analysis,
with events such as vaginal bleeding, night sweats, and hot
Xushes more common in the tamoxifen arm, and bone frac-
tures, arthralgia, low-grade hypercholesterolemia, and mis-
cellaneous cardiovascular events observed more frequently
in the letrozole group (Coates et al. 2007). Of note, throm-
boembolic events continued to be signiWcantly reduced
with letrozole vs. tamoxifen (P < 0.001), and the endpoints
of any cardiac event, ischemic heart disease, and cardiac
failure were not signiWcantly diVerent between the groups.
Results of the BIG 1-98 primary core analysis, obtained
at a relatively early follow-up, as well as results from the
exploratory monotherapy arm analysis, obtained at a longer
follow-up, thus establish letrozole as a more eVective alter-
native to tamoxifen in the initial adjuvant setting, and this
eVect appears to be especially pronounced on early distant
metastases events. A recent analysis evaluating the predic-
tors of early relapse in BIG 1-98 (N = 5,890 patients) dem-
onstrated that distant metastases events constituted the
majority of early events (within 2 years) (Mauriac et al.
2007); at this time, letrozole had already demonstrated a
30% reduction in the risk for distant metastases over
tamoxifen (Thurlimann et al. 2005). This beneWcial eVect
of letrozole in reducing early distant metastases is compel-
ling given the adverse impact of distant metastases on sur-
vival, and should ultimately result in reduced breast cancer
speciWc mortality, although this remains to be proven on
longer follow-up.
Trials investigating AIs in the switch adjuvant setting
These trials have all generally investigated a strategy
involving early treatment with tamoxifen for 2–3 years, fol-
lowed by an AI as adjuvant therapy for the remainder of the
5-year treatment period. It is important to note that the
deWned switching period only includes those events starting
from the switch point (after the end of tamoxifen therapy, at
which time patients would either continue on tamoxifen or
switch to an AI) until the study end.
ITA trial
This open-label trial compared the eYcacy of a switch to
anastrozole following 2–3 years of previous tamoxifen
therapy with continued tamoxifen in 448 high-risk ER+
patients (99% N+, 67% chemotherapy pretreatment) (Boc-
cardo et al. 2005a, b). The switch from tamoxifen to anas-
trozole was associated with a signiWcant reduction in breast
cancer events (event-free survival and progression-free sur-
vival) and a 43% improvement in distant-progression-free
survival at either the 36-month follow-up (HR = 0.49; 95%
CI 0.22–1.05; P = 0.06) or the 52-month follow-up
(Table 2), with a marked reduction in locoregional recur-
rences at both of these follow-up points (36-month:
HR = 0.15; P = 0.003; 52-month: HR = 0.13; P = 0.002)
(Boccardo et al. 2005b). More lipid disorders were seen
with patients who switched to anastrozole (9.3% vs. 4.0%;
P = 0.04), while more gynecologic changes, including
endometrial carcinoma, were observed in the patients on
tamoxifen compared with anastrozole (11.3% vs. 1.0%;
P = 0.0002), and signiWcantly more SAEs were observed
with tamoxifen (22% vs. 13.9%; P = 0.04) (Boccardo et al.
2005a). Results of this trial thus suggest that switching to
anastrozole after 2–3 years of tamoxifen results in fewer
recurrences compared with continuing on tamoxifen.
Combined ARNO 95/ABCSG 8 analysis
The ARNO 95 and ABCSG 8 trials were also designed to
evaluate the impact of a switch to anastrozole following
2 years of tamoxifen. An important diVerence in inclusion
criteria, however, was that women were randomized pre-
treatment with tamoxifen in ABCSG 8 and after 2 years of
tamoxifen in ARNO 95 (Jakesz et al. 2005a). The com-
bined analysis examined events in 3,224 patients (1,606
continuing tamoxifen and 1,618 switching to anastrozole)
at a median of 28 months following the initial treatment
with tamoxifen (Jakesz et al. 2005a). Results demonstrated
a 40% reduction in events with anastrozole vs. tamoxifen,
and a 39% reduction in distant metastases (Table 2). Of
note, distant metastases accounted for 62% of recurrences
in women whose disease progressed, and this occurred in123
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treated patients; the HR for distant metastases as Wrst events
only was 0.54 in univariate analysis (95% CI 0.37–0.80;
P = 0.0016). By comparison, contralateral or ipsilateral
recurrences accounted for only 16 and 28% of recurrences,
respectively (Table 2). Results of this combined analysis
thus suggest that switching to anastrozole after 2 years of
tamoxifen is associated with reductions in distant breast
cancer recurrences and recurrences overall, although no
improvement in OS was observed. When considering only
the ARNO 95 trial, however (N = 979), at 30.1 months of
follow-up, Cox proportional hazards analysis demonstrated
a 39% improvement in DFS (38 events vs. 56 events;
HR = 0.66; 95% CI 0.44–1.00; P = 0.049), as well as a 47%
improvement in OS (15 anastrozole deaths vs. 28 tamoxi-
fen deaths; HR, 0.53; 95% CI 0.28–0.99; P = 0.045) (Kauf-
mann et al. 2007).
Combined analysis: ABCSG 8/ARNO 95/ ITA trials
A further combined analysis of results from the ABCSG 8,
ARNO 95, and ITA switching trials, which vary in trial
design, patient populations, size, and doses of tamoxifen
used, has been undertaken (Jonat et al. 2006). Results of
this combined analysis of 4,006 patients (2,009 on anas-
trozole and 1,997 on tamoxifen), with a median follow-up
of 30 months, demonstrated a signiWcant 41% improvement
in DFS, a 39% improvement in distant metastases-free sur-
vival, and a 29% improvement in OS with anastrozole com-
pared with tamoxifen (Table 2). Patients switching to
anastrozole experienced fewer recurrences (92 vs. 159) and
deaths (66 vs. 90). The DFS beneWt of switching to anas-
trozole vs. continuing on tamoxifen was also observed in
patients with tumors >2 cm (HR = 0.57), those with one to
three positive nodes (HR = 0.66), those with four or more
positive nodes (HR = 0.43), and those receiving prior che-
motherapy (HR = 0.33). These results thus suggest that the
clinical beneWt of anastrozole in terms of DFS ultimately
translates into an OS beneWt, and that physicians may con-
sider switching patients currently taking adjuvant tamoxi-
fen to an AI after 2–3 years.
The IES
The eYcacy and safety of exemestane when used in the
switch setting (following 2–3 years of tamoxifen) has also
been examined in the IES. In this study, recurrence-free
patients were randomized, after completing 2–3 years of
tamoxifen, to either further tamoxifen or exemestane to
complete 5 years of adjuvant therapy (Coombes et al.
2004). Initial results at a median follow-up of 30.6 months
showed that there was a signiWcant 32% beneWt of exemes-
tane over tamoxifen in DFS (HR = 0.68; P < 0.001) and a
signiWcant 34% reduction in the risk of developing distant
metastases (HR = 0.66; P = 0.0004), but only a trend
toward improvement in OS (HR = 0.88; P = 0.37).
Results of the IES at 55.7 months of follow-up demon-
strated a signiWcant 24% improvement in DFS, a signiWcant
17% improvement in TTDM, and a non-signiWcant 15%
improvement in OS (Table 2). When only ER+ or unknown
patients were included, the corresponding improvements in
these endpoints was 25% (HR = 0.75; P = 0.0001), 18%
(HR = 0.82; P = 0.03), and 17% (HR = 0.83; P = 0.05),
with the latter OS endpoint being marginally signiWcant
(Coombes et al. 2007). After adjusting for ER+ status and
pre-speciWed prognostic factors (e.g., nodal status and che-
motherapy use), the diVerence in OS reached signiWcance
(HR = 0.83; P = 0.04). Results of the IES thus suggest that
a switch to exemestane, like anastrozole, is more eVective
than continuing tamoxifen, and this beneWt results in a sur-
vival advantage in ER+ patients. Moreover, they indicate
that a signiWcant reduction in the risk of distant metastases
may predict a beneWt in mortality related to breast cancer
with longer follow-up.
AEs were similar to those seen in the initial analysis, with
fewer thromboembolic events (1.9% vs. 3.1%; P = 0.01),
fewer serious gynecological AEs (6.4% vs. 9.8%;
P < 0.001), and signiWcantly more fractures (7.0% vs. 4.9%;
P = 0.003) and arthralgia (20.8% vs. 15.1%; P < 0.001) in
the exemestane group compared with the tamoxifen group
(Coombes et al. 2007). Also, patients who switched to exe-
mestane showed an increased incidence of ischemic cardiac
events (9.9% vs. 8.6%; P = 0.12), angina (7.1% vs. 6.5%;
P = 0.44), and myocardial infarction (1.3% vs. 0.8%;
P = 0.08), although this was not statistically signiWcant.
Can we identify a superior AI or AI adjuvant strategy?
The best adjuvant strategy is one that will allow for maxi-
mal long-term eYcacy with good tolerability and a minimal
risk of AEs that could lead to drug discontinuation. EYcacy
is especially important in the early adjuvant setting, where
the risk for breast cancer recurrence is greatest. Results
from the ATAC and BIG 1-98 trials have demonstrated the
superiority of AIs (anastrozole and letrozole, respectively)
over tamoxifen in reducing recurrence risk in the initial
adjuvant setting (Howell et al. 2005; Coates et al. 2007;
Thurlimann et al. 2005) (Table 2). As detailed above,
results from the IES, ABCSG 8, ARNO 95, and ITA trials
also demonstrate that the switch to an AI (exemestane or
anastrozole) after 2–3 years of adjuvant tamoxifen is more
eVective than continuing tamoxifen alone for 5 years, and a
marginal survival beneWt has also been demonstrated with
this strategy (Coombes et al. 2007; Jonat et al. 2006)
(Table 2). In view of these emerging data concerning the123
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ogy Assessment Team, the 2005 St Gallen consensus panel,
and the National Comprehensive Cancer Network guide-
lines now include AIs as initial adjuvant therapy as an
option for patients with endocrine-responsive disease
(anastrozole and letrozole) and in the switch adjuvant set-
ting (anastrozole and exemestane) (Goldhirsch et al. 2005;
Carlson et al. 2006; Winer et al. 2005).
A comparison of risk reduction among the diVerent AI
trials might suggest on the surface that sequencing tamoxi-
fen with an AI seems to provide a better relative risk reduc-
tion than the upfront use of an AI alone (e.g., compare
initial and switch adjuvant trials; Table 2). Such compari-
sons, however, are not appropriate, because the patient pop-
ulations selected in the switch setting diVer from those in
the initial adjuvant setting. It must be remembered that
patients whose disease has recurred during the 2–3 years of
tamoxifen therapy are excluded from the switching trials
but not from the initial adjuvant trials (Pritchard 2005). It
can also be argued that, by excluding these patients as well
as patients who could not tolerate tamoxifen from the trial
populations examined, one has already pre-selected a good
prognosis patient population, one that has been shown to be
responsive to endocrine therapy after 2–3 years of tamoxi-
fen (Coombes et al. 2007; Boccardo et al. 2005a, Jakesz
et al. 2005a; Kaufmann et al. 2006). Results of the switch-
ing trials have only demonstrated that there is a beneWt in
switching to AIs in patients disease-free after 2–3 years on
tamoxifen.
In terms of tolerability, the side-eVect proWles of the AIs
diVer from that of tamoxifen but appear to be generally
similar across the three available drugs. The AIs thus oVer
beneWts over tamoxifen in terms of risks for endometrial
cancer and thromboembolic events at the expense of poten-
tial AEs on bone loss, and neutral eVects on lipid proWles
and cardiovascular health (Coombes et al. 2007; Boccardo
et al. 2005a; Goss et al. 2005; Howell et al. 2005; Jakesz
et al. 2005a; Thurlimann et al. 2005). There also appears to
be no appreciable diVerence in terms of side eVects when
AIs are given as initial adjuvant therapy or as switch adju-
vant therapy. Both initial and switch trials showed
increased rates of gynecological events, including endome-
trial abnormalities, and thromboembolic events with
tamoxifen compared with AIs, and increased rates of mus-
culoskeletal events, including bone loss, with AIs com-
pared with tamoxifen (Coombes et al. 2007; Boccardo
et al. 2005a; Howell et al. 2005; Jakesz et al. 2005a;
Thurlimann et al. 2005). Although both strategies also
demonstrated increased rates of hypercholesterolemia and
cardiac events with AIs compared with tamoxifen (Coom-
bes et al. 2007; Boccardo et al. 2005a; Howell et al. 2005;
Jakesz et al. 2005a; Thurlimann et al. 2005), these
increases are not apparent in trials comparing AIs with
placebo (Goss et al. 2005) and are likely explained by the
cardioprotective eVects that have been observed with
tamoxifen (Braithwaite et al. 2003; EBCTCG 2005). In
addition, neither treatment strategy has had a detrimental
eVect on patient quality of life in studies that have evalu-
ated this endpoint (FallowWeld et al. 2004, 2006). While
there are some arguments to support a prospectively
planned sequencing strategy of tamoxifen with an AI in
certain patients, i.e., those with low risk of recurrence, the
only sequential trial that has reported results to date,
ABCSG 8, has not yet shown any signiWcant DFS beneWt
(P = 0.07) for the AI arm (tamoxifen followed by anastroz-
ole vs. 5 years of initial adjuvant tamoxifen (Jakesz
2005b). Also, when considering the high rate of early
recurrences, especially early distant metastases, the excess
of SAEs, and withdrawals associated with adjuvant tamox-
ifen therapy in the Wrst few years post surgery, the use of an
AI over tamoxifen, in the time of this peak of recurrence
risk, appears justiWable (Houghton 2005).
Additional data from the sequential arms of the BIG 1-
98 trial are expected within the next 2 years. Once avail-
able, these should provide further information on the use of
AIs (sequential vs. upfront) and any potential safety bene-
Wts of one approach vs. the other (Pritchard 2005). Until
such data become available, it may be prudent to have all
patients, and not just those at increased risk of relapse,
begin their adjuvant therapy with the strongest available
treatment in order to most eVectively reduce the early
relapse risk.
Several other unanswered questions remain regarding
endocrine therapy. Studies to address the optimal duration
of adjuvant AI therapy include MA.17R and NSABP B-42;
both will examine whether there is an additional beneWt
with longer use of AIs (Goss 2006; Mamounas et al. 2006).
In the MA.17R study, women who have successfully com-
pleted 5 years of extended adjuvant letrozole therapy
(either in the MA.17 trial or routine clinical practice) will
then be randomized to receive 5 more years of letrozole or
placebo (Goss 2006). In the NSABP B-42 trial, the eYcacy
of 5 years of letrozole vs. placebo is being investigated in
postmenopausal women with HR+ breast cancer patients
who have completed 5 years of endocrine therapy (Mamo-
unas et al. 2006)
In addition, the Femara Reanalysed Through Genomics
for Response Assessment, Calibration and Empowerment
(FRAGRANCE) trial is investigating the genetic determi-
nants responsible for de novo resistance to letrozole (Clini-
calTrials.gov NCT00199134). Two other trials, Microarray
In Node-Negative Disease May Avoid Chemotherapy
(MINDACT) and Trial Assigning IndividuaLized Options
for Treatment (TAILORx), are examining whether genetic
testing can aid in the selection of the appropriate adjuvant
treatment strategy, including the need for chemotherapy,123
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ClinicalTrials.gov NCT00433589).
Which AI therapy, if any, is more eVective and/or better
tolerated than the others, whether used in the initial adju-
vant or switch adjuvant setting, is not known. There are at
present no results from large, well-controlled trials that
directly compare the individual AIs with each other as adju-
vant therapy in the same population. Upcoming results
from at least two trials should provide more directly com-
parative eYcacy and safety data for individual AIs. The
MA.27 trial is comparing anastrozole with exemestane in
the initial adjuvant setting (Pritchard 2005; ClinicalTri-
als.gov NCT00066573). The Femara vs. Anastrozole Clini-
cal Evaluation (FACE) trial is evaluating the eYcacy and
safety of 5 years of adjuvant anastrozole vs. letrozole as ini-
tial adjuvant therapy with the increased-risk population of
N+ patients, so that the results may be obtained more
quickly (DeBoer et al. 2006). Another trial with exemes-
tane, the Tamoxifen and Exemestane Adjuvant Multicenter
(TEAM) trial, was started in 2001 to compare exemestane
or tamoxifen as adjuvant monotherapy for 5 years but was
then amended, based on the results from IES, to investigate
sequencing from tamoxifen to exemestane after 2 to 3 years
in comparison with 5 years of exemestane (Markopoulos
et al. 2006; ClinicalTrials.gov NCT00032136). Publication
of eYcacy results is still pending.
Conclusions
While the AIs have a proven superiority over tamoxifen
when used as either initial or switch adjuvant therapy
(Howell et al. 2005; Coombes et al. 2007; Thurlimann et al.
2005; Boccardo et al. 2005a; Jakesz et al. 2005a), the opti-
mal AI and adjuvant strategy remains a matter of debate.
The use of AIs rather than tamoxifen, with either strategy,
is supported by good clinical data, and there appears to be
little diVerence in safety with either approach. The upcom-
ing results from the sequential arms of the BIG 1-98 trial
may provide some data as to which strategy (AI upfront or
used sequentially), if either, is most eVective and/or is bet-
ter tolerated. In the meantime, while awaiting these data
and those from directly comparative AI studies such as
FACE and MA.27, it is clear that patients with endocrine-
sensitive breast cancer remain at a substantial risk for recur-
rence, especially during the early years after surgery, and
that there is a risk for early distant relapse, and conse-
quently death from breast cancer, in women with N+ and
with N¡ disease. Distant metastases recurrence events are
the most common type of early relapse event, and for post-
menopausal patients with endocrine-sensitive breast cancer,
beginning therapy with an AI oVers the best opportunity to
reduce the risk of early relapse. Of note, letrozole is partic-
ularly eVective at reducing the risk of distant metastases in
patients with HR+ tumors in the initial adjuvant setting. An
AI should be used as early as possible in the course of treat-
ment, as the increased risks of early recurrence observed
with tamoxifen cannot be oVset by the later use of an AI.
On the other hand, for patients who did not have the chance
to start with an AI upfront, using an AI sequentially after
tamoxifen is a reasonable option and provides greater pro-
tection against relapse than continuing on tamoxifen.
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